Default company panoramic image
Logo

Mantis BioLogics Inc.

Mantis BioLogics has developed the first patented assay of HDL function that can accurately predict a person’s cardiovascular risk.

  • Stage Concept Only
  • Industry Not Set
  • Location Vancouver, BC, Canada
  • Currency CAD

Company Summary

Aside from direct visualiztion of the coronary artery tree, there is no reliable test to determine patient risk for coronary artery disease (CAD). Mantis BioLogics developed a rapid, precise and cost-effective means of determining CAD risk. Automation of this process will enable screening of approximately 110 million patients annually, far more reliably than current methods allow, with an estimated annual market of over $1B.

Team

  • Default avatar
    Shawn Hayes
    CEO

  • Default avatar
    Michael Oda
    Founder and CSO

  • Default avatar
    Michelle Bouchard
    Consultant

  • Default avatar
    Cheryl Wellington
    Consultant

  • Default avatar
    Josh Schultz
    Consultant